About
Small Molecules for Tumors
Areas of Focus
Categories
Small Molecule PharmaceuticalChina
Clinical Trials (41)
View allTotal Trials
41
As Lead Sponsor
17
As Collaborator
24
Total Enrollment
1,902
By Phase
NA: 7PHASE1/PHASE2: 9PHASE1: 9PHASE2: 9PHASE4: 1EARLY_PHASE1: 1PHASE2/PHASE3: 2
By Status
COMPLETED: 13RECRUITING: 9TERMINATED: 6NOT_YET_RECRUITING: 4ACTIVE_NOT_RECRUITING: 4UNKNOWN: 3WITHDRAWN: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline41 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
Hover over trial bars to see details
Recent Trials
NCT06225050Lead Sponsor
M-2018-334 in Hematological Malignancies
NANot yet recruiting
18 participants
Started: Oct 31, 2025 · Completed: Oct 31, 2028
NCT07178431Lead Sponsor
MB-CART2019.1 in Refractory Multiple Sclerosis
PHASE1/PHASE2Not yet recruiting
26 participants
Started: Oct 30, 2025 · Completed: Dec 30, 2030
NCT07020260Collaborator
The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies
PHASE1/PHASE2Not yet recruiting
18 participants
Started: Sep 1, 2025 · Completed: Sep 1, 2028
NCT07137494Collaborator
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
PHASE1Recruiting
12 participants
Started: Aug 14, 2025 · Completed: Aug 31, 2028
NCT06508931Lead Sponsor
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms
PHASE2Recruiting
31 participants
Started: Aug 4, 2025 · Completed: Dec 31, 2029
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...